Haleon plc (NYSE:HLN) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Haleon plc (NYSE:HLN) have been given a consensus rating of “Buy” by the six brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $10.95.

Several equities analysts recently weighed in on HLN shares. UBS Group raised Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley increased their price objective on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th.

Institutional Trading of Haleon

A number of institutional investors and hedge funds have recently modified their holdings of the company. Fortitude Family Office LLC acquired a new position in Haleon in the third quarter worth about $28,000. Toronto Dominion Bank raised its holdings in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after buying an additional 3,470 shares in the last quarter. Cultivar Capital Inc. bought a new position in shares of Haleon during the 2nd quarter worth approximately $40,000. Prospera Private Wealth LLC acquired a new stake in Haleon in the 3rd quarter valued at $57,000. Finally, BOKF NA grew its position in Haleon by 68.8% in the second quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after acquiring an additional 2,842 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Performance

Shares of HLN opened at $9.72 on Tuesday. The company has a market capitalization of $44.00 billion, a PE ratio of 28.59, a price-to-earnings-growth ratio of 2.95 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon has a one year low of $7.89 and a one year high of $10.80. The company’s fifty day moving average price is $9.74 and its 200 day moving average price is $9.54.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.